• Revenues of € 17.0 million
• EBIT of € 3.5 million, 21% margin
• Profit after tax € 4.6 million
• Forecast for fiscal year 2024/2025
  • Slight increase in sales from € 17.0 million to € 17.5 million
  • EBIT between € 3.5 million and € 4.0 million

Bremen, January 30, 2025 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, announces its results for the fiscal year 2023/2024, with reporting period October 1, 2023 to September 30, 2024.

Revenues in the past fiscal year 2023/2024 amounted to €17.0 million (compared to €17.3 million in fiscal year 2022/2023). 25 % of sales revenues (previous year: 26%) are attributable to the sale of licenses, 35 % (previous year: 36 %) to maintenance revenues and 40 % (previous year: 38 %) to other revenues, which include, among other things, services for and recharges to affiliated companies and the parent company. The decline in license revenues compared to the previous year is mainly due to lower demand from our customers Philips and Canon. Maintenance revenues have fallen due to lower maintenance revenues from our customer Hologic. The year-on-year improvement in other revenues is due to a slight increase in diagnostic services and the reallocation of staff costs, rent and additional costs.

EBIT (earnings before interest and taxes) fell from € 3,895 k in the previous year to € 3,500 k in 2023/2024, mainly due to lower revenues, lower other operating income and higher staff costs. The EBIT margin fell accordingly from 23 % to 21 %.

Due to the tax group, only a small amount of income taxes of €0.1 million were incurred in the past financial year, the same as in the previous year.

This results in earnings after taxes of € 4.6 million (27 % margin) for fiscal year 2023/2024, compared to € 4.9 million (28 % margin) in 2022/2023. The profit of € 4,561 k will be transferred to Varex Imaging Deutschland AG under the domination and profit and loss transfer agreement .

For fiscal year 2024/2025, stable to slightly growing revenues in the range of € 17.0 million to € 17.5 million are expected. In addition to stable revenues from customer Hologic, slightly increasing revenues in the lung and liver segments are expected. In the area of development services, we expect a stable course. For earnings before interest and taxes (EBIT) for fiscal year 2024/2025 we expect a result between € 3.5 million and € 4.0 million, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in sales and the simultaneous disproportionately low increase in staff costs are the main drivers for the positive outlook for EBIT.

The half-year financial report for fiscal year 2024/2025 will be published on May 27, 2025.